Bio-Rad Laboratories Posts Mixed Q4 2025 Financial Results
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Bio-Rad Laboratories ( (BIO) ).
Bio-Rad Laboratories reported financial results on February 12, 2026 for the fourth quarter and full year ended December 31, 2025, posting modest revenue growth amid a difficult macro backdrop of geopolitical uncertainty and constrained academic and biotech funding. The Life Science segment saw sales decline for both the quarter and full year on a currency-neutral basis, while the Clinical Diagnostics segment delivered solid growth driven by quality controls, blood typing, and diabetes products, with gains across all regions.
For the fourth quarter, total net sales rose 3.9 percent year over year to $693.2 million, but GAAP gross margin slipped to 49.8 percent and the company recorded a loss from operations, reflecting margin pressure and a $172.8 million impairment of purchased intangibles. Non‑GAAP operating income and margins also declined versus the prior year, underscoring operational headwinds despite revenue gains in diagnostics.
Full-year 2025 revenue inched up 0.7 percent to $2,583.2 million, essentially flat on a currency-neutral basis, as Life Science weakness offset modest Clinical Diagnostics growth. Bio-Rad generated non‑GAAP net income of $270.5 million, down from 2024, but reported a GAAP net income of $759.9 million—versus a large loss in 2024—primarily due to a favorable change in the fair market value of its investment in Sartorius AG, partially offset by the intangibles impairment and a higher effective tax rate.
Strategically, Bio-Rad expanded its Droplet Digital PCR leadership through the acquisition and integration of Stilla Technologies and advanced its oncology diagnostics strategy via partnerships with Gencurix and Biodesix to distribute and develop in vitro diagnostic oncology assays. The company also broadened global access to over 1,200 clinical diagnostics products through new registrations in more than 60 countries, strengthened commercial leadership with the appointment of Rajat Mehta as Executive Vice President of Global Commercial Operations, and delivered $532 million in cash from operations and $375 million in free cash flow.
Looking ahead to full-year 2026, Bio-Rad guided to non‑GAAP, currency-neutral revenue growth of approximately 0.5 to 1.5 percent and an expected non‑GAAP operating margin of about 12.0 to 12.5 percent. This outlook signals a cautious growth trajectory as the company focuses on improving profitability and capitalizing on its expanded ddPCR and oncology diagnostics platforms while navigating funding and reimbursement pressures in its end markets.
The most recent analyst rating on (BIO) stock is a Hold with a $340.00 price target. To see the full list of analyst forecasts on Bio-Rad Laboratories stock, see the BIO Stock Forecast page.
Spark’s Take on BIO Stock
According to Spark, TipRanks’ AI Analyst, BIO is a Neutral.
Bio-Rad Laboratories faces significant financial challenges, with declining profitability and mixed cash flow performance being the most impactful factors. Technical analysis suggests a potential bearish trend, while valuation metrics are unattractive due to negative earnings. The earnings call provided some positive insights, but overall, the stock’s outlook remains cautious.
To see Spark’s full report on BIO stock, click here.
More about Bio-Rad Laboratories
Bio-Rad Laboratories, Inc. is a global leader in life science research and clinical diagnostics products, developing, manufacturing, and marketing tools used in academic, biotech, and healthcare laboratories. The company’s portfolio spans droplet digital PCR technologies, quality controls, blood typing, diabetes testing, and a broad range of clinical diagnostics assays with a growing international footprint.
Average Trading Volume: 196,260
Technical Sentiment Signal: Sell
Current Market Cap: $8.09B
Learn more about BIO stock on TipRanks’ Stock Analysis page.
